Q-omics provides the consensus-scored ATP11A profile across patient tissues and cancer cell-line models. ATP11A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP11A is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, ATP11A RNA expression shows 20,034 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where ATP11A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP11A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP11A survival associations across molecular data types. ATP11A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP11A RNA expression–survival associations across cancer types. High ATP11A expression shows unfavorable associations in BLCA, LUSC, CESC, ACC and MESO, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP11A RNA expression.
This table summarizes ATP11A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ATP11A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP11A shows lower tumor expression in KICH and higher tumor expression in COAD, KIRC, HNSC, STAD and KIRP. The COAD box plot shows higher ATP11A RNA expression in tumor versus normal tissue (log2 FC = +2.711, t-test p < 0.001).
This table shows molecular features associated with ATP11A in patient tissues and cancer cell lines. In patient samples, ATP11A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP11A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
